论文部分内容阅读
目的:探讨埃索美拉唑与奥美拉挫三联疗法治疗胃溃疡临床疗效及安全性。方法:随机选取我院2013年6月到2014年6月收治的100例胃溃疡患者作为研究对象,对照组50例接受奥美拉唑三联治疗,试验组50例接受埃索美拉唑三联治疗。均治疗4周后观察两组患者的治疗有效率及HP根除率,做比较分析。结果:临床观察发现,试验组接受埃索美拉唑三联治疗溃疡有效率位94.00%,显著高于对照组的82.00%,试验组HP根除率94.00%也明显高于对照组的76.00%,差异均有统计学意义(p<0.05)。结论:埃索美拉唑三联与奥美拉唑三联具有更明显的疗效,临床不良反应小,HP根除率高,较适合临床普及运用。
Objective: To investigate the clinical efficacy and safety of esomeprazole and omeprazole triple therapy in the treatment of gastric ulcer. Methods: A total of 100 patients with gastric ulcer admitted to our hospital from June 2013 to June 2014 were randomly selected. 50 patients in the control group received omeprazole triple therapy and 50 patients in the experimental group received esomeprazole triple therapy . After 4 weeks of treatment, the treatment efficiency and HP eradication rate in both groups were observed and compared. Results: The clinical observation showed that in the experimental group, the effective rate of ulcer with esomeprazole triple therapy was 94.00%, significantly higher than that of the control group (82.00%). The HP eradication rate in the experimental group was also significantly higher than that of the control group (76.00%, 94.00% All were statistically significant (p <0.05). Conclusion: The combination of esomeprazole triple and omeprazole has more obvious curative effect, small clinical adverse reaction and high HP eradication rate, which is suitable for clinical popularization.